Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E22.24 EPS (ttm)1.41 Insider Own0.02% Shs Outstand6.17B Perf Week0.06%
Market Cap193.41B Forward P/E13.34 EPS next Y2.35 Insider Trans-17.71% Shs Float6.16B Perf Month-12.57%
Income8.91B PEG3.95 EPS next Q0.51 Inst Own73.30% Short Float0.74% Perf Quarter-8.15%
Sales48.20B P/S4.01 EPS this Y-14.50% Inst Trans-1.85% Short Ratio1.92 Perf Half Y-8.01%
Book/sh10.86 P/B2.89 EPS next Y14.08% ROA5.40% Target Price39.17 Perf Year10.82%
Cash/sh4.91 P/C6.39 EPS next 5Y5.63% ROE12.60% 52W Range26.61 - 36.18 Perf YTD3.20%
Dividend1.12 P/FCF30.23 EPS past 5Y3.10% ROI8.90% 52W High-13.32% Beta0.88
Dividend %3.57% Quick Ratio1.90 Sales past 5Y0.10% Gross Margin81.30% 52W Low17.87% ATR1.00
Employees78300 Current Ratio2.10 Sales Q/Q-50.90% Oper. Margin28.70% RSI (14)32.73 Volatility2.79% 2.81%
OptionableYes Debt/Eq0.53 EPS Q/Q-47.50% Profit Margin18.50% Rel Volume1.64 Prev Close32.22
ShortableYes LT Debt/Eq0.40 EarningsJul 28 BMO Payout75.50% Avg Volume23.80M Price31.36
Recom2.30 SMA20-8.70% SMA50-8.60% SMA200-5.39% Volume38,985,181 Change-2.67%
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
Sep-01-15 05:07PM  Pfizer's Effort to Toss Medicaid Lawsuit Seemingly Unsuccessful at The Wall Street Journal
09:00AM  Europe gets Amgen cholesterol drug for 50-60 pct of U.S. price Reuters
Aug-31-15 06:15PM  Should You Sell GE, AT&T, Pfizer? Check Weekly Charts at Investor's Business Daily
04:01PM  The 4 Stocks That Hobbled the Dow on Monday at 24/7 Wall St.
02:16PM  5 Dividend Stocks With Upside Potential: Apple Inc. (AAPL), Microsoft Corporation (MSFT) & More at Insider Monkey
01:20PM  20 Healthcare Stocks The Richest Hedge Fund Billionaires Are Buying And Selling Now at Forbes
09:30AM  The Zacks Analyst Blog Highlights: 3M Company, General Electric, Intel and Johnson & Johnson
06:01AM  Navigating through Volatility
Aug-28-15 04:40PM  Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
04:01PM  The 4 Stocks That Held Down the DJIA on Friday at 24/7 Wall St.
03:14PM  What You Need To Know About 2 New S&P 500 Members
12:58PM  Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside at TheStreet
11:04AM  Dow 30 Stock Roundup: 3M Lowers 2015 Earnings Outlook, JNJ Subsidiary Sells Splenda
09:45AM  Research and Markets: China Latanoprost Market Investigation Report 2010-2019 Business Wire
09:08AM  Big Lots goes big; Aeropostale misses; Smith & Wesson shoots higher
06:25AM  Ahead of the Bell: Activision Blizzard, United join S&P 500
Aug-27-15 09:10PM  Amgen wins approval for second biotech cholesterol drug
06:15PM  Cramer: China & biotech - it's complicated
05:35PM  Activision Blizzard, United Continental Holdings Set to Join the S&P 500 PR Newswire
05:27PM  Trade S&P 500 changes
04:06PM  Tracking today's volatility
03:58PM  At the close: Stocks snap back
01:47PM  FDA proposes adding suffixes to distinguish biosimilar drug names Reuters
09:15AM  Deutsche Bank Says Stick With Top Stocks Growing Dividends at 24/7 Wall St.
Aug-26-15 04:27PM  More dividend cuts looming?
04:12PM  MannKind And Afrezza: Can The Drug Cure The Company? at Forbes
09:08AM  AstraZenecas CVMD Segment: How Did It Perform in 2Q15?
08:05AM  Short Sellers Have Mixed Feelings on Major Pharma at 24/7 Wall St.
07:30AM  Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone ReceptorPositive Early Breast Cancer Business Wire
Aug-25-15 02:34PM  Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application at Forbes
10:10AM  Company News for August 25, 2015
Aug-24-15 07:39PM  Pfizer says Hospira purchase will close in early September
02:30PM  Accelerated Buybacks Less Favorable During Market Swoons at The Wall Street Journal
02:09PM  Pfizer Gets Approval For Hospira Acquisition
11:28AM  Pfizer (PFE) Stock Lower, Receives Regulatory Approval for Hospira Purchase at TheStreet
08:31AM  Pfizer Buy of Hospira Gets Green Light at The Wall Street Journal
08:15AM  Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015 Business Wire
08:00AM  Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition Business Wire
Aug-23-15 07:01PM  Even best stocks hit hard: Pisani
Aug-21-15 06:41PM  Pfizer's (PFE) Breast Cancer Drug Ibrance Under EU Review
08:00AM  Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine) Business Wire
Aug-20-15 03:24PM  Valeant bets on pink pill
03:23PM  Valeant To Buy Addyi Maker Sprout, But Stock Wilts at Investor's Business Daily
02:42PM  Disinflation, Not Deflation
11:53AM  Drug industry links run deep in field of sexual medicine
11:23AM  Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer Business Wire
08:42AM  Valeant snaps up Female Viagra maker Sprout for $1 billion at Fortune
Aug-19-15 04:12PM  MannKind Backers Still Drinking The Kool-Aid As Stock Slips Below $4 at Forbes
12:06AM  FDA approves first pill aimed at boosting female libido
Aug-18-15 09:02PM  FDA approves female sex pill, but with safety restrictions
08:51PM  You Can Call It The 'Female Viagra', But The Libido Pill, Addyi, Won't Come Close To Viagra's Impact at Forbes
07:47PM  3 plays on rocky biotechnology sector at CNBC
07:05PM  Pfizers Revised Financial Guidance for 2015
05:43PM  Something Big Is Happening With Big Pharma at Motley Fool
05:00PM  3 Ways to play biotech breakthroughs
04:01PM  Why Monitoring US Net Exports May Be Crucial Right Now
09:31AM  EU mergers and takeovers (Aug 18) Reuters
Aug-17-15 11:51AM  Who Should Allergan Buy? at Barrons.com
05:45AM  Research and Markets: Investigation Report on China's Glipizide Market 2015-2019 Business Wire
05:32AM  Research and Markets: China Sertraline Market Investigation Report 2010-2019 Business Wire
Aug-16-15 08:06AM  Whats in Pfizers Product Pipeline?
Aug-14-15 05:47PM  Drug execs behind female libido pill have run afoul of FDA
04:36PM  Boomers, Pharmacists And Mergers
01:07PM  Kyle Bass' pharma plays
12:38PM  Dollar Appreciation Impacts IBMs Growth in 2Q15
10:44AM  Teva Pharmaceutical Industries Ltd. Earnings Q2*, 2015
10:06AM  Pfizers Revenue Falls by 7% in 2Q15
08:35AM  Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition Business Wire
Aug-13-15 06:06PM  What Contributed to Pfizers Growth in 2Q15?
01:04PM  PFIZER INC Financials
09:05AM  P&Gs Health Care Business Had the Highest Organic Sales Growth
08:28AM  Why M&A Doesn't Make Sense For Pfizer Anytime Soon
08:15AM  Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira Business Wire
08:01AM  5 Things Pfizer inc. Wants You to Know at Motley Fool
Aug-12-15 05:03PM  Pfizer Stock Is Like An Extended Release Drug at Investopedia
05:00PM  Pfizers Improving Growth Rate in 2Q15
04:59PM  Pfizer Stock Rises on Positive 2Q15 Earnings Results
09:45AM  Short Sellers Back Off Big Pharma at 24/7 Wall St.
Aug-11-15 08:13AM  Once Disparaged, 'Me-Too' Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs at Forbes
Aug-10-15 02:21PM  When Must I Buy a Stock to Get the Dividend? at TheStreet
12:25PM  5 Defensive High-Yield Dividends That Should Withstand the Next Stock Market Correction at 24/7 Wall St.
08:00AM  Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder PR Newswire
Aug-08-15 08:10PM  10-Q for Pfizer Inc. at Company Spotlight
Aug-07-15 11:15AM  Europe Regulator Approves Pfizer Buyout of Hospira at Investopedia
08:42AM  U.K. Accuses Pfizer of Inflating Drug's Price at The Wall Street Journal
01:00AM  Pfizer, Bristol revive cancer drugs that rev up immune system
12:00AM  Glaxo's Best Headache' Remedy May Be Buying Stakes in Ventures
Aug-06-15 06:15PM  Allergan CEO: Bold is our tagline
04:01PM  The 4 Stocks That Dragged Down the DJIA on Thursday at 24/7 Wall St.
04:01PM  Why Pfizer Should Pay Close Attention to the Allergan-Teva Deal at Motley Fool
11:47AM  ARIAD Slips on Wider-than-Expected Q2 Loss; Iclusig Grows - Analyst Blog
08:35AM  4 Large Cap Pharmaceutical Stocks to Buy on Strong Health Care Trends at 24/7 Wall St.
08:03AM  UK watchdog accuses Pfizer of inflating anti-epilepsy drug price at Financial Times
07:51AM  Britain raps Pfizer over huge jump in epilepsy drug price Reuters
07:42AM  China gets tougher for Western drugmakers Reuters
05:29AM  Research and Markets: Investigation Report on China's Atorvastatin Market, 2010-2019 Featuring Ebang Pharmaceutical, Pfizer, Topfond & Beijing Jialin Pharmaceutical Business Wire
05:13AM  Research and Markets: Investigation Report on China's Celecoxib Market, 2010-2019 Featuring Pfizer & Shire Business Wire
02:47AM  Britain raps Pfizer over inflated epilepsy drug prices Reuters
12:01AM  APCER Life Sciences Appoints Dr. Sutinder Bindra as Global Head of Medical Affairs, Opens Hong Kong Office Business Wire
Aug-05-15 05:37PM  CVS strips Viagra, other top drugs, from insurance coverage
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM